- Home
- KRNY vs GOSS Comparison
KRNY vs GOSS Comparison
Compare KRNY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNY
- GOSS
- Stock Information
- Founded
- KRNY 1884
- GOSS 2015
- Country
- KRNY United States
- GOSS United States
- Employees
- KRNY N/A
- GOSS N/A
- Industry
- KRNY Savings Institutions
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- KRNY Finance
- GOSS Health Care
- Exchange
- KRNY Nasdaq
- GOSS Nasdaq
- Market Cap
- KRNY 389.4M
- GOSS 347.8M
- IPO Year
- KRNY 2005
- GOSS 2019
- Fundamental
- Price
- KRNY $6.04
- GOSS $1.96
- Analyst Decision
- KRNY Buy
- GOSS Strong Buy
- Analyst Count
- KRNY 2
- GOSS 4
- Target Price
- KRNY $7.75
- GOSS $8.50
- AVG Volume (30 Days)
- KRNY 381.4K
- GOSS 3.2M
- Earning Date
- KRNY 07-24-2025
- GOSS 08-05-2025
- Dividend Yield
- KRNY 7.28%
- GOSS N/A
- EPS Growth
- KRNY N/A
- GOSS N/A
- EPS
- KRNY 0.42
- GOSS N/A
- Revenue
- KRNY $151,629,000.00
- GOSS $40,237,000.00
- Revenue This Year
- KRNY $13.01
- GOSS N/A
- Revenue Next Year
- KRNY N/A
- GOSS $63.97
- P/E Ratio
- KRNY $14.48
- GOSS N/A
- Revenue Growth
- KRNY 12.84
- GOSS N/A
- 52 Week Low
- KRNY $5.45
- GOSS $0.66
- 52 Week High
- KRNY $8.59
- GOSS $2.23
- Technical
- Relative Strength Index (RSI)
- KRNY 44.90
- GOSS 58.35
- Support Level
- KRNY $5.87
- GOSS $1.67
- Resistance Level
- KRNY $6.25
- GOSS $2.00
- Average True Range (ATR)
- KRNY 0.16
- GOSS 0.17
- MACD
- KRNY 0.02
- GOSS -0.02
- Stochastic Oscillator
- KRNY 52.83
- GOSS 52.21
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.